THERAPEUTIC FOCUS

Hidradenitis suppurativa is a severely debilitating chronic skin condition resulting in irreversible tissue destruction

HS manifests as painful inflammatory skin lesions such as nodules and abscesses, typically around the armpits, groin and buttocks. Over time, uncontrolled and inadequately-treated inflammation can result in the formation of draining dermal tunnels and scarring.

The disease is expected to be inadequately diagnosed in many patients and prevalence rates vary largely between below 0.1% and up to 4% of the global population, with three times more females affected than males. Onset typically occurs in early adulthood and has a profound negative impact on quality of life, with higher morbidity than other dermatologic conditions.

There is increasing scientific evidence to support IL-17A-and IL-17F-mediated inflammation as a key driver of the pathogenesis of HS, with other identified risk factors including genetics, cigarette smoking, and obesity.

Psoriatic arthritis (PsA)
Psoriasis
Hidradenitis suppurativa (HS)